Since its founding in 2013, OpenBiome shipped more than 56,000 FMT preparations to a network of 1,250 healthcare facilities. The organization now operates as a research and knowledge platform rather than an active treatment provider, positioning itself within a competitive landscape that includes commercial players like Seres Therapeutics (FDA-approved pill form) and research-focused microbiome companies advancing defined bacterial therapeutics.
Cyborg Score Rationale
OpenBiome established foundational infrastructure and expertise in microbiome therapeutics but faces a transitional challenge. Regulatory shifts forced its exit from direct FMT delivery, though it maintains influence through research and clinical guidance. The competitive landscape increasingly favors defined bacterial therapies and commercialized solutions over stool banking.
Top Insights
Regulatory pressures shifted OpenBiome from operational stool banking to research and infrastructure roles, reflecting FDA's tightening oversight of stool-based biologics.
The microbiome therapeutics market is moving from whole-stool FMT toward defined bacterial strains and pill formulations (e.g., Seres Vowst FDA approval in April 2023).
OpenBiome trained 1,250+ healthcare facilities and shipped 56,000+ FMT preparations, establishing strong clinical and institutional relationships despite operational pivot.
C. difficile remains the validated indication; broader microbiome applications show mixed efficacy, limiting market expansion beyond infectious disease.
Named Competitors
Vowst — FDA-approved fecal microbiota therapeutic pill for C. difficile
Microbiome Therapeutics — Defined bacterial strain therapies replacing stool donation
Microbiome Therapies — Stool-derived microbiome treatments for C. difficile
Rebiotix Therapies — Microbiota restoration therapies for recurrent infection
Recent Developments
(February 2021) Announced plan to wind down stool bank operations following regulatory changes
(April 2023) Competitor Seres Therapeutics received FDA approval for first fecal transplant pill (Vowst), validating microbiome therapeutic category
(Current) OpenBiome refocused on research support, clinician education, and microbiome infrastructure rather than direct patient treatment delivery
Open the full interactive OpenBiome report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.